This document outlines a hematology slide presentation on a case of pediatric leukemia. Key details include a 13-year-old boy with low hemoglobin, low platelets, and 50% atypical cells on blood smear. The presentation examines blood and bone marrow smears under different magnifications and discusses the provisional diagnosis of acute leukemia. It then provides an outline on the discussion of pediatric leukemia covering etiology, epidemiology, clinical features, laboratory studies including morphology, cytochemistry, immunophenotyping and cytogenetics, and differential diagnosis.
A short presentation on the diagnostic procedure involved in Leukemia identification and possible treatment available currently. This presentation includes the types of leukemia, risk factors, symptoms, treatment methods, and advanced techniques.
This document provides an overview of acute myeloid leukemia (AML). It discusses the etiology, classification, clinical features, laboratory findings, treatment including induction chemotherapy, post-remission therapy such as stem cell transplantation, and prognostic factors of AML. The key points are that AML is a cancer of the myeloid line of blood cells, its incidence increases with age, and treatment involves induction chemotherapy to achieve remission followed by post-remission therapy to prevent relapse.
acute and chronic Leukemia therapy by irfan hamidayeshahmed786
The document presents information on leukemia therapy. It begins with definitions of leukemia as malignant disorders of hematopoietic tissues associated with increased white blood cells. It then discusses the types and classification of both acute and chronic leukemias. The key differences between acute and chronic leukemias as well as myeloid and lymphoid leukemias are summarized. Treatment approaches for acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) including induction, consolidation, and maintenance are outlined. Specific drugs used to treat AML are also listed.
This document discusses leukemias and provides information about leukemoid reactions. It defines a leukemoid reaction as a high white blood cell count with neutrophilia usually in response to infection, which can mimic chronic myelogenous leukemia or acute myeloid leukemia. The document notes that serum leukocyte alkaline phosphatase is normally elevated in leukemoid reactions, distinguishing it from CML where it is depressed. Features suggesting a leukemoid reaction rather than leukemia include toxic granulation, a high LAP score, and an obvious cause of the neutrophilia such as infection. The document provides several potential causes of leukemoid reactions and discusses methods for distinguishing leukemoid reactions from leukemia.
This document discusses leukocyte disorders and provides information about acute leukemia. It defines leukocytosis and leukopenia as increases or decreases in white blood cell count. Non-neoplastic causes of changes in white blood cells include neutrophilia, lymphocytosis, eosinophilia, monocytosis, and basophilia. Neoplastic disorders include acute myeloid leukemia and acute lymphoblastic leukemia. The document outlines the classification, pathogenesis, clinical features, diagnosis and treatment of acute leukemias. Diagnosis involves examination of blood and bone marrow smears, cytochemistry, immunophenotyping, cytogenetics and molecular analysis to determine the leukemia subtype and guide treatment.
acute leukemia
For More Medicine Free PPT - http://playnever.blogspot.com/
For Health benefits and medicine videos Subscribe youtube channel - https://www.youtube.com/playlist?list=PLKg-H-sMh9G01zEg4YpndngXODW2bq92w
This document outlines a hematology slide presentation on a case of pediatric leukemia. Key details include a 13-year-old boy with low hemoglobin, low platelets, and 50% atypical cells on blood smear. The presentation examines blood and bone marrow smears under different magnifications and discusses the provisional diagnosis of acute leukemia. It then provides an outline on the discussion of pediatric leukemia covering etiology, epidemiology, clinical features, laboratory studies including morphology, cytochemistry, immunophenotyping and cytogenetics, and differential diagnosis.
A short presentation on the diagnostic procedure involved in Leukemia identification and possible treatment available currently. This presentation includes the types of leukemia, risk factors, symptoms, treatment methods, and advanced techniques.
This document provides an overview of acute myeloid leukemia (AML). It discusses the etiology, classification, clinical features, laboratory findings, treatment including induction chemotherapy, post-remission therapy such as stem cell transplantation, and prognostic factors of AML. The key points are that AML is a cancer of the myeloid line of blood cells, its incidence increases with age, and treatment involves induction chemotherapy to achieve remission followed by post-remission therapy to prevent relapse.
acute and chronic Leukemia therapy by irfan hamidayeshahmed786
The document presents information on leukemia therapy. It begins with definitions of leukemia as malignant disorders of hematopoietic tissues associated with increased white blood cells. It then discusses the types and classification of both acute and chronic leukemias. The key differences between acute and chronic leukemias as well as myeloid and lymphoid leukemias are summarized. Treatment approaches for acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) including induction, consolidation, and maintenance are outlined. Specific drugs used to treat AML are also listed.
This document discusses leukemias and provides information about leukemoid reactions. It defines a leukemoid reaction as a high white blood cell count with neutrophilia usually in response to infection, which can mimic chronic myelogenous leukemia or acute myeloid leukemia. The document notes that serum leukocyte alkaline phosphatase is normally elevated in leukemoid reactions, distinguishing it from CML where it is depressed. Features suggesting a leukemoid reaction rather than leukemia include toxic granulation, a high LAP score, and an obvious cause of the neutrophilia such as infection. The document provides several potential causes of leukemoid reactions and discusses methods for distinguishing leukemoid reactions from leukemia.
This document discusses leukocyte disorders and provides information about acute leukemia. It defines leukocytosis and leukopenia as increases or decreases in white blood cell count. Non-neoplastic causes of changes in white blood cells include neutrophilia, lymphocytosis, eosinophilia, monocytosis, and basophilia. Neoplastic disorders include acute myeloid leukemia and acute lymphoblastic leukemia. The document outlines the classification, pathogenesis, clinical features, diagnosis and treatment of acute leukemias. Diagnosis involves examination of blood and bone marrow smears, cytochemistry, immunophenotyping, cytogenetics and molecular analysis to determine the leukemia subtype and guide treatment.
acute leukemia
For More Medicine Free PPT - http://playnever.blogspot.com/
For Health benefits and medicine videos Subscribe youtube channel - https://www.youtube.com/playlist?list=PLKg-H-sMh9G01zEg4YpndngXODW2bq92w
1) The Chronic Myeloproliferative Disorders (CMPDs) are a group of malignant stem cell disorders characterized by clonal proliferation of one or more myeloid cell lineages.
2) CMPDs include Chronic Myeloid Leukemia (CML), Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Myelofibrosis.
3) CML is caused by the Philadelphia chromosome, a translocation between chromosomes 9 and 22 that produces the BCR-ABL fusion gene and its constitutively active tyrosine kinase, and progresses through chronic, accelerated, and blast crisis phases if left untreated.
Dr. Huda Dardeer provides an overview of leukaemia, including the different types: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL). She discusses their causes, presentations, investigations, classifications, and treatments. Leukaemia results from abnormal proliferation of immature white blood cells. The main types are differentiated based on the cell lineage involved and disease progression. Treatment involves supportive care as well as cell-specific chemotherapy, immunotherapy, stem cell transplant, or targeted therapies like imatinib.
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow characterized by increased proliferation of immature blast cells. It results from mutations that affect the common myeloid progenitor cell. Symptoms include fatigue, fever, bleeding, and infections. Diagnosis involves blood and bone marrow tests showing elevated white blood cell counts with immature blasts. Standard treatment is 7-day continuous cytarabine with 3-day daunorubicin induction chemotherapy, with hematopoietic stem cell transplant for high risk cases. Prognosis depends on risk factors like age and genetic abnormalities.
Leukemia is the most common pediatric malignancy, accounting for 1/3 of all childhood cancers. It is defined as the malignant clonal proliferation of lymphoid or myeloid precursor cells in the bone marrow and infiltration of other organs. The presentation includes general symptoms like fever, fatigue, and pallor as well as hematological effects from bone marrow invasion including anemia, neutropenia, and thrombocytopenia. Diagnosis involves blood tests, bone marrow examination, and other investigations. Treatment consists of induction chemotherapy followed by consolidation and maintenance therapy to achieve remission and prevent relapse.
The document discusses different types of leukemia, including acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). It describes the signs, symptoms, diagnosis, and classification of leukemias. The most common type of childhood leukemia is acute lymphoblastic leukemia (ALL), which accounts for approximately 80% of cases in children.
Leukaemia is a group of malignant blood disorders affecting the bone marrow and blood-forming tissues. There are four main types classified by whether the affected cells are lymphoid or myeloid, and whether the disease course is acute or chronic. Acute leukemias involve immature blast cells and a rapid progression, while chronic leukemias involve more mature cells and a slower course. The document defines each type and discusses their signs, symptoms, diagnosis, prognostic factors and treatment approaches.
This document discusses acute myeloid leukemia (AML) and its acute complications. It defines AML as a clonal expansion of myeloid precursor cells with reduced capacity to differentiate. Common clinical presentations include fever, bleeding, and fatigue due to excessive proliferation of myeloid cells in the bone marrow leading to pancytopenia. Two major acute complications discussed are leukostasis, which can cause pulmonary and neurological symptoms, and tumor lysis syndrome, which results in electrolyte abnormalities and renal impairment.
This document provides an overview of chronic myeloid leukemia (CML), including its molecular genetics, clinical manifestations, diagnosis, treatment options and outcomes. CML results from a fusion of the BCR and ABL genes, forming the Philadelphia chromosome and BCR-ABL fusion protein. It progresses through chronic, accelerated and blast crisis phases if left untreated. Tyrosine kinase inhibitors are now the standard first-line treatment and can control the disease long-term in chronic phase, while allogeneic stem cell transplant remains the only potential cure. Resistance and disease progression remain challenges.
This document provides information about leukemia, including its types and treatments. It defines leukemia as cancer of the white blood cells that develops in the bone marrow. There are four main types classified as either acute or chronic, and affecting either lymphocytic or myeloid cells. Symptoms can include fatigue, infections, and bruising. Diagnosis involves blood and bone marrow tests. Treatments include chemotherapy, radiation, bone marrow transplants, and new drugs that target specific genetic mutations in leukemia cells. Research continues on developing more effective treatments and potential cures.
An update of Acute leukemia in children.pptTareqHasanRana
This document provides information about leukemia, including its types and treatments. It begins by defining leukemia as cancer of the blood cells. There are four main types of leukemia classified by how quickly they progress and what type of blood cell is affected: acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia. Symptoms can include fatigue, infections, bruising, and bone pain. Diagnosis involves blood and bone marrow tests. Treatments may include chemotherapy, radiation therapy, immunotherapy, bone marrow transplants, and new drugs. Research continues on developing more effective treatments and potential cures.
This slide presentation summarizes the case of a 50-year-old man with fatigue and weight loss who was found to have lymphocytosis, anemia, hepatosplenomegaly, and lymphadenopathy. Peripheral blood smear, bone marrow biopsy, flow cytometry and cytogenetic testing supported a diagnosis of chronic lymphocytic leukemia (CLL) stage III. He was started on chemoimmunotherapy but did not improve, so he was considered for bone marrow transplantation. The presentation provides details on the epidemiology, clinical features, diagnostic criteria, prognostic factors, treatment approaches and histological transformation of CLL.
B. Myelodysplastic syndrome (MDS) is the most likely diagnosis. MDS is characterized by dysplastic cells of all three lineages in the bone marrow, leading to peripheral cytopenias. The findings of macrocytic anemia, thrombocytopenia, and Pelger-Huet neutrophils on blood film are consistent with MDS. The bone marrow biopsy also showed a normocellular marrow. MDS commonly presents in the elderly and has no known cause in many cases.
Acute leukemias are malignant disorders characterized by the clonal expansion of immature blood cells in the bone marrow and other organs. There are two main types - acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). AML results from mutations that block myeloid cell differentiation while ALL occurs when mutations interfere with lymphocyte development. Patients present with anemia, bleeding, infections, and organ infiltration. Diagnosis involves blood tests, bone marrow biopsy, and other exams. Treatment requires supportive care and specific chemotherapy, which may include stem cell transplantation in some cases.
MPNs are clonal hematopoietic stem cell disorders characterized by overproduction of one or more myeloid cell lineages in the bone marrow and blood. The key subtypes include CML, PV, PMF, and ET. CML is driven by the Philadelphia chromosome and BCR-ABL1 fusion gene. PV is characterized by elevated red blood cell counts and the JAK2 V617F mutation in over 95% of cases. Without treatment, MPNs can progress to more advanced stages including myelofibrosis, leukemia, or transformation. Molecular testing plays an important role in diagnosis and classification.
This document discusses the case of a 35-year-old female patient presenting with fever, fatigue, and shortness of breath. Her medical history includes a hysterectomy for menorrhagia and treatment for genitourinary tuberculosis. On examination, she has pallor and tachycardia. Laboratory tests show pancytopenia and blasts in her peripheral blood smear. A bone marrow biopsy confirms the diagnosis of acute myeloid leukemia. The discussion reviews the epidemiology, etiology, classification, clinical presentation, diagnostic workup, and initial treatment evaluation for AML.
This document discusses the presentation, diagnosis, prognostic factors, and treatment approach for childhood acute leukemias. It covers common presentations of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Diagnosis involves morphology, cytochemistry, immunophenotyping, and identifying genetic abnormalities. Prognostic factors for ALL include age, gender, white blood cell count, immunophenotype, and cytogenetics. Treatment involves induction chemotherapy, consolidation therapy, cranial irradiation or intrathecal chemotherapy for ALL, and hematopoietic stem cell transplantation may be used for high-risk patients. Supportive care including managing infections, tumor lysis syndrome, and blood product transfusions is also discussed.
This document discusses the presentation, diagnosis, prognostic factors, and treatment approach for childhood acute leukemias. It covers common presentations of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Diagnosis involves morphology, cytochemistry, immunophenotyping, and identifying genetic abnormalities. Prognostic factors for ALL include age, gender, white blood cell count, immunophenotype, and cytogenetics. Treatment involves induction chemotherapy, consolidation therapy, cranial irradiation or intrathecal chemotherapy for ALL, and hematopoietic stem cell transplantation may be used for high risk patients. Supportive care including managing infections, tumor lysis syndrome, and blood product transfusions is also discussed.
This document provides information about acute lymphoblastic leukemia (ALL). It discusses that ALL is a cancer of the lymphoid cells that is most common in children. The document covers the classification, immunologic subtypes, cytogenetic abnormalities, clinical features, diagnostic measures, and hematological and histological findings of ALL. It describes that ALL is diagnosed based on complete blood count, peripheral smear, bone marrow biopsy and cytogenetic/flow cytometry analysis. The key diagnostic findings include anemia, leukocytosis, thrombocytopenia and lymphoblasts in the bone marrow.
This document discusses hepatoblastoma (HB), a rare type of liver cancer that primarily affects young children. It provides details on:
- The causes of HB including genetic mutations and syndromes.
- Presenting symptoms like abdominal swelling and jaundice.
- Diagnosis involving blood tests, imaging like CT/MRI, and biopsy.
- Staging HB using the PRETEXT and POSTTEXT systems to determine if the tumor can be surgically removed.
- Treatment options including chemotherapy, radiation, surgery, and targeted therapy.
- Prognosis factors like age, tumor markers, and response to initial treatment.
This document discusses the genetics and inheritance of blood groups, focusing on the ABO system. It explains that the ABO system is determined by three genes - A, B, and O - located on chromosome 9. These genes encode glycosyltransferase enzymes that add specific sugars to a basic oligosaccharide chain on red blood cells, producing the A, B, and H antigens. The presence or absence of these antigens determines the individual's blood group type. Proper understanding of blood group genetics is important for blood transfusions to avoid immune reactions between incompatible blood types.
More Related Content
Similar to Introduction of Hematol.Malignancy .ppt
1) The Chronic Myeloproliferative Disorders (CMPDs) are a group of malignant stem cell disorders characterized by clonal proliferation of one or more myeloid cell lineages.
2) CMPDs include Chronic Myeloid Leukemia (CML), Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Myelofibrosis.
3) CML is caused by the Philadelphia chromosome, a translocation between chromosomes 9 and 22 that produces the BCR-ABL fusion gene and its constitutively active tyrosine kinase, and progresses through chronic, accelerated, and blast crisis phases if left untreated.
Dr. Huda Dardeer provides an overview of leukaemia, including the different types: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL). She discusses their causes, presentations, investigations, classifications, and treatments. Leukaemia results from abnormal proliferation of immature white blood cells. The main types are differentiated based on the cell lineage involved and disease progression. Treatment involves supportive care as well as cell-specific chemotherapy, immunotherapy, stem cell transplant, or targeted therapies like imatinib.
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow characterized by increased proliferation of immature blast cells. It results from mutations that affect the common myeloid progenitor cell. Symptoms include fatigue, fever, bleeding, and infections. Diagnosis involves blood and bone marrow tests showing elevated white blood cell counts with immature blasts. Standard treatment is 7-day continuous cytarabine with 3-day daunorubicin induction chemotherapy, with hematopoietic stem cell transplant for high risk cases. Prognosis depends on risk factors like age and genetic abnormalities.
Leukemia is the most common pediatric malignancy, accounting for 1/3 of all childhood cancers. It is defined as the malignant clonal proliferation of lymphoid or myeloid precursor cells in the bone marrow and infiltration of other organs. The presentation includes general symptoms like fever, fatigue, and pallor as well as hematological effects from bone marrow invasion including anemia, neutropenia, and thrombocytopenia. Diagnosis involves blood tests, bone marrow examination, and other investigations. Treatment consists of induction chemotherapy followed by consolidation and maintenance therapy to achieve remission and prevent relapse.
The document discusses different types of leukemia, including acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). It describes the signs, symptoms, diagnosis, and classification of leukemias. The most common type of childhood leukemia is acute lymphoblastic leukemia (ALL), which accounts for approximately 80% of cases in children.
Leukaemia is a group of malignant blood disorders affecting the bone marrow and blood-forming tissues. There are four main types classified by whether the affected cells are lymphoid or myeloid, and whether the disease course is acute or chronic. Acute leukemias involve immature blast cells and a rapid progression, while chronic leukemias involve more mature cells and a slower course. The document defines each type and discusses their signs, symptoms, diagnosis, prognostic factors and treatment approaches.
This document discusses acute myeloid leukemia (AML) and its acute complications. It defines AML as a clonal expansion of myeloid precursor cells with reduced capacity to differentiate. Common clinical presentations include fever, bleeding, and fatigue due to excessive proliferation of myeloid cells in the bone marrow leading to pancytopenia. Two major acute complications discussed are leukostasis, which can cause pulmonary and neurological symptoms, and tumor lysis syndrome, which results in electrolyte abnormalities and renal impairment.
This document provides an overview of chronic myeloid leukemia (CML), including its molecular genetics, clinical manifestations, diagnosis, treatment options and outcomes. CML results from a fusion of the BCR and ABL genes, forming the Philadelphia chromosome and BCR-ABL fusion protein. It progresses through chronic, accelerated and blast crisis phases if left untreated. Tyrosine kinase inhibitors are now the standard first-line treatment and can control the disease long-term in chronic phase, while allogeneic stem cell transplant remains the only potential cure. Resistance and disease progression remain challenges.
This document provides information about leukemia, including its types and treatments. It defines leukemia as cancer of the white blood cells that develops in the bone marrow. There are four main types classified as either acute or chronic, and affecting either lymphocytic or myeloid cells. Symptoms can include fatigue, infections, and bruising. Diagnosis involves blood and bone marrow tests. Treatments include chemotherapy, radiation, bone marrow transplants, and new drugs that target specific genetic mutations in leukemia cells. Research continues on developing more effective treatments and potential cures.
An update of Acute leukemia in children.pptTareqHasanRana
This document provides information about leukemia, including its types and treatments. It begins by defining leukemia as cancer of the blood cells. There are four main types of leukemia classified by how quickly they progress and what type of blood cell is affected: acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia. Symptoms can include fatigue, infections, bruising, and bone pain. Diagnosis involves blood and bone marrow tests. Treatments may include chemotherapy, radiation therapy, immunotherapy, bone marrow transplants, and new drugs. Research continues on developing more effective treatments and potential cures.
This slide presentation summarizes the case of a 50-year-old man with fatigue and weight loss who was found to have lymphocytosis, anemia, hepatosplenomegaly, and lymphadenopathy. Peripheral blood smear, bone marrow biopsy, flow cytometry and cytogenetic testing supported a diagnosis of chronic lymphocytic leukemia (CLL) stage III. He was started on chemoimmunotherapy but did not improve, so he was considered for bone marrow transplantation. The presentation provides details on the epidemiology, clinical features, diagnostic criteria, prognostic factors, treatment approaches and histological transformation of CLL.
B. Myelodysplastic syndrome (MDS) is the most likely diagnosis. MDS is characterized by dysplastic cells of all three lineages in the bone marrow, leading to peripheral cytopenias. The findings of macrocytic anemia, thrombocytopenia, and Pelger-Huet neutrophils on blood film are consistent with MDS. The bone marrow biopsy also showed a normocellular marrow. MDS commonly presents in the elderly and has no known cause in many cases.
Acute leukemias are malignant disorders characterized by the clonal expansion of immature blood cells in the bone marrow and other organs. There are two main types - acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). AML results from mutations that block myeloid cell differentiation while ALL occurs when mutations interfere with lymphocyte development. Patients present with anemia, bleeding, infections, and organ infiltration. Diagnosis involves blood tests, bone marrow biopsy, and other exams. Treatment requires supportive care and specific chemotherapy, which may include stem cell transplantation in some cases.
MPNs are clonal hematopoietic stem cell disorders characterized by overproduction of one or more myeloid cell lineages in the bone marrow and blood. The key subtypes include CML, PV, PMF, and ET. CML is driven by the Philadelphia chromosome and BCR-ABL1 fusion gene. PV is characterized by elevated red blood cell counts and the JAK2 V617F mutation in over 95% of cases. Without treatment, MPNs can progress to more advanced stages including myelofibrosis, leukemia, or transformation. Molecular testing plays an important role in diagnosis and classification.
This document discusses the case of a 35-year-old female patient presenting with fever, fatigue, and shortness of breath. Her medical history includes a hysterectomy for menorrhagia and treatment for genitourinary tuberculosis. On examination, she has pallor and tachycardia. Laboratory tests show pancytopenia and blasts in her peripheral blood smear. A bone marrow biopsy confirms the diagnosis of acute myeloid leukemia. The discussion reviews the epidemiology, etiology, classification, clinical presentation, diagnostic workup, and initial treatment evaluation for AML.
This document discusses the presentation, diagnosis, prognostic factors, and treatment approach for childhood acute leukemias. It covers common presentations of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Diagnosis involves morphology, cytochemistry, immunophenotyping, and identifying genetic abnormalities. Prognostic factors for ALL include age, gender, white blood cell count, immunophenotype, and cytogenetics. Treatment involves induction chemotherapy, consolidation therapy, cranial irradiation or intrathecal chemotherapy for ALL, and hematopoietic stem cell transplantation may be used for high-risk patients. Supportive care including managing infections, tumor lysis syndrome, and blood product transfusions is also discussed.
This document discusses the presentation, diagnosis, prognostic factors, and treatment approach for childhood acute leukemias. It covers common presentations of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Diagnosis involves morphology, cytochemistry, immunophenotyping, and identifying genetic abnormalities. Prognostic factors for ALL include age, gender, white blood cell count, immunophenotype, and cytogenetics. Treatment involves induction chemotherapy, consolidation therapy, cranial irradiation or intrathecal chemotherapy for ALL, and hematopoietic stem cell transplantation may be used for high risk patients. Supportive care including managing infections, tumor lysis syndrome, and blood product transfusions is also discussed.
This document provides information about acute lymphoblastic leukemia (ALL). It discusses that ALL is a cancer of the lymphoid cells that is most common in children. The document covers the classification, immunologic subtypes, cytogenetic abnormalities, clinical features, diagnostic measures, and hematological and histological findings of ALL. It describes that ALL is diagnosed based on complete blood count, peripheral smear, bone marrow biopsy and cytogenetic/flow cytometry analysis. The key diagnostic findings include anemia, leukocytosis, thrombocytopenia and lymphoblasts in the bone marrow.
Similar to Introduction of Hematol.Malignancy .ppt (20)
This document discusses hepatoblastoma (HB), a rare type of liver cancer that primarily affects young children. It provides details on:
- The causes of HB including genetic mutations and syndromes.
- Presenting symptoms like abdominal swelling and jaundice.
- Diagnosis involving blood tests, imaging like CT/MRI, and biopsy.
- Staging HB using the PRETEXT and POSTTEXT systems to determine if the tumor can be surgically removed.
- Treatment options including chemotherapy, radiation, surgery, and targeted therapy.
- Prognosis factors like age, tumor markers, and response to initial treatment.
This document discusses the genetics and inheritance of blood groups, focusing on the ABO system. It explains that the ABO system is determined by three genes - A, B, and O - located on chromosome 9. These genes encode glycosyltransferase enzymes that add specific sugars to a basic oligosaccharide chain on red blood cells, producing the A, B, and H antigens. The presence or absence of these antigens determines the individual's blood group type. Proper understanding of blood group genetics is important for blood transfusions to avoid immune reactions between incompatible blood types.
Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer with a high mortality rate.
Other name: hepatoma
HCC often develops in patients with chronic liver disease
Hepatoblastoma is a disease in which malignant (cancer) cells form in the tissues of the liver. It
is the most common type of childhood liver cancer and usually affects children younger than 3 years of age
Ewing's sarcoma is a rare type of cancer that occurs most often in the bones of the legs and pelvis in children and young adults under 20 years old. It is characterized by the genetic translocation t(11;22)(q24;q12) which fuses the EWS and FLI1 genes. Diagnosis involves patient history, physical exam, imaging tests like x-rays, CT, MRI and bone scans to identify tumors and metastases commonly in the lungs and bones. Pathological and molecular testing is also used to identify the genetic translocation.
This document discusses megaloblastic anemia, its causes, symptoms, and diagnostic tests. It begins by defining megaloblastic anemia as a group of disorders caused by deficiencies in vitamin B12 or folic acid. These deficiencies result in impaired DNA synthesis and defective cell maturation. Key symptoms include anemia, diarrhea/constipation, and glossitis. Diagnostic tests involve measuring serum levels of B12, folate, and homocysteine. Pernicious anemia, a type of megaloblastic anemia, is also discussed and is characterized by autoimmune destruction of gastric parietal cells and the absence of intrinsic factor.
This document discusses different types of normocytic anemia, including anemia of chronic disease (ACD), sideroblastic anemia (SA), and aplastic anemia (AA). ACD is characterized by mild, non-progressive anemia associated with chronic inflammatory or malignant diseases. SA results from a defect in hemoglobin synthesis that causes iron to accumulate in bone marrow cells. AA is a hypoproliferative disorder defined by pancytopenia and a failure of the bone marrow to produce all blood cell types.
The document discusses anemia classification and investigation tests. It provides definitions and classifications of anemia based on red blood cell count, hemoglobin, and hematocrit levels. The main types of anemia are outlined as blood loss, deficient red blood cell production, and excessive red blood cell destruction. A complete blood count, blood film, iron tests, and bone marrow examination are important tests to evaluate the cause of anemia. The reticulocyte count helps indicate whether the bone marrow is responding to the anemia.
This document discusses complete blood count (CBC) tests, which are commonly used to evaluate important components in the blood. A CBC provides information about red blood cells, white blood cells, platelets, and can help diagnose diseases affecting the blood. It discusses how CBC results are used to diagnose anemia and other disorders. The document also compares manual and automated methods for performing CBC tests, noting advantages of automation like speed, reduced costs, and producing more reproducible results. Indices derived from CBC results, like MCV, MCH, and MCHC are also introduced as they can provide clues to the type of anemia present.
Osteosarcoma is a type of bone cancer that usually develops in the osteoblast cells that form bone. It occurs most often in children, adolescents, and young adults. Symptoms may include pain in the affected bone, swelling, limping, and decreased movement. Diagnosis involves medical history, physical exam, blood tests, biopsy of the tumor, and imaging tests like X-rays, CT, MRI, and bone scans. Treatment may include surgery to remove the tumor, chemotherapy, radiation therapy, rehabilitation, and continued follow-up care. Osteosarcoma has a high rate of metastasis, usually to the lungs, so combination therapy is often used for higher-grade tumors.
Langerhans cell histiocytosis (LCH) is a condition characterized by the proliferation of abnormal Langerhans cells. Langerhans cells are a type of immune cell normally found in the skin that present antigens and activate T cells. In LCH, these cells accumulate in tissues in an idiopathic manner. Presentation varies from rashes and skin lesions to organ infiltration in bones, causing pain and swelling. Diagnosis involves patient history, clinical exams, blood tests, biopsy for histopathology, and radiological imaging to detect osteolytic lesions. LCH has characteristics of both a reactive process and neoplastic disorder, with unclear pathophysiology thought to involve interactions between abnormal Langerhans
This document discusses pediatric non-Hodgkin lymphoma (NHL). It begins by introducing NHL and stating that it is categorized into immature and mature B or T-cell NHL. It then discusses specific types of NHL in more detail in 3 sentences or less each:
Follicular lymphoma is the most common form of indolent NHL and develops from abnormal B lymphocytes that grow in lymph node follicles. Diffuse large B cell lymphoma is an aggressive NHL that develops from abnormal, larger B cells spread diffusely in tissues. Anaplastic large cell lymphoma is a T-cell lymphoma characterized by large, rapidly dividing cells that are typically CD30 positive and sometimes have a chromosomal translocation involving the
This document discusses qualitative defects of granular white blood cells that can result in morphological or functional changes. These defects are either inherited or acquired. Some specific acquired disorders discussed include hyposegmentation, hypersegmentation, toxic changes in neutrophils, May-Hegglin anomaly, Alder's anomaly, Chediak-Higashi syndrome, and myeloperoxidase deficiency. The key signs and symptoms of each condition are described.
The spleen plays important roles in filtering blood and immune function. It is divided into red pulp, white pulp, and marginal zones, each with distinct functions. The spleen filters red blood cells, supports hematopoiesis, removes antigens from blood for immune processing, and stores platelets and white blood cells. Diseases can cause the spleen to enlarge (splenomegaly) or overwork (hypersplenism), requiring its surgical removal (splenectomy) to improve blood counts.
the RBC production and maturation completed in the bone marrow normally, all the maturation stages of erythropoiesis are descriped here and how regulated ..etc
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
ABDOMINAL TRAUMA in pediatrics part one.drhasanrajab
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
NVBDCP.pptx Nation vector borne disease control program
Introduction of Hematol.Malignancy .ppt
1. Developed by
Dr.Abdulrazzaq Othman Alagbare-MD-MCP-
Hematology Lecturer
INTRODUCTION
hematological- malignant Disorders
FOR Clinical LABORATORY STUDENTS
2. The Malignant Hematological Disorders
Means malignancy for all blood cells that produce from the bone marrow
1-Leukemia for the following
cells
a) Neutrophil
b) Eosinophil
c) Basophil
d) Monocyte
e) T-Lymphocyte
f) B-Lymphocyt
2-RBC:
Polycythemia Vera (PV)
3-Thrombocytes : Essential
Thrombocythemia (ET)
4-Plasm cells
Multiple myeloma (MM)
3. Introduction-Leukemia
Definition: Leukemia is a cancer of blood white cells
Caused by the mutation of
pluripotent or most
primitive stem cells. (PSC,
MSC, LSC)
Blast cells accumulate in the Bone
marrow and
1. peripheral blood
2. Spleen
3. Lymph nodes
4. Liver
The leukemic cells are
1. Trapped early from the B.M
2. Proliferate without control (No effect of growth factors)
3. Not able to carry out their function
4. fetal disease if not treated
1
4. 1- Myeloid group malignancies
Granullar cells ––> (N. E. and B ) Leukemias
Monocytes ––> Monocytic leukemia
Erythrocytes ––> Polycythemia vera
Platelets ––> Essential thrombocythemia
2- Lymphoid group malignancies
B-lymphocytes ––> Leukemias
T-lymphocytes ––> Leukemias
Plasma cells ––> Multiple myeloma
5. Causes of leukemia or Predisposing factors
1. Inherited factors
2. Environmental
factors
3. Infection
genetic diseases e.g.
Down's syndrome,
Klinefelter's syndrome,
Fanconi's anemia,
Chemicals e.g.
Benzene
Drugs e.g.
Alkylating agents
Radiation
Viruses e.g. Epstein-Barr virus EBV, HIV,
Human herpes virus 8 (HHV-8)
Bacteria e.g. Helicobacter Pylori
Protozoa e.g. Malaria
6. FAB classification
The FAB classification is based largely on.
1-Morphology of cells
2-Simple cytochemical stains
1. At least 30% of cells in the
bone marrow or blood must be
myeloblasts.
2. and does not include cytogenetic
abnormalities
But must be
7. Differences between acute and chronic leukemia
1- Cells maturation degree (blast or mature )
2-Blood cells count in the peripheral blood
3-Patient`s symptoms
4-Clinical onset
5-organomegaly
6-patient`s age
All Leukemia divided into Acute and chronic
8. Properties of acute leukemia Properties of chronic leukemia
Immature cells (90% blast cells ) More mature cells (60%-70% mature cells)
Occurs in all ages Usually occurs in adults and elderly
Clinical onset is sudden Clinical onset is gradual
Anemia and thrombocytopenia are severe Anemia and thrombocytopenia are mild
WBC is variable (high, normal or low with 90 %
blast cells)
WBC is increased , abnormal cells, (30% blast )
organomegaly is mild Organomegaly is prominent
9. Clinical Picture of acute
leukemias
Clinical Picture of chronic
leukemias
The patient has
1. Anemia
2. Bleeding
3. Infection
The patient has
1. No anemia
2. No bleeding
3. No Infection
Acute leukemia cause morbidity and mortality through :-
1. Deficiency in blood cell number and function
2. Invasion of vital organs
3. Systemic disturbances by metabolic imbalance
10. Pathophysiology
Acute leukemia cause morbidity and mortality through :-
1. Deficiency in blood cell number and function
2. Invasion of vital organs
3. Systemic disturbances by metabolic imbalance
11. Investigations need to diagnose leukemia
1. Complete blood count.(CBC or FBC)
2. Peripheral blood film inspection
3. A bone marrow examination
4. Flow cytometry or immunophenotyping studies
5. Chromosomal analysis
6. Cytochemical stains
12. 1-Complete blood count show
1. The RBC changes
2. WBC: count,
3. Platelets: count and morphology
PBS: show
1. Changes of white blood cells,
2. % of blast cells
3. Type of blast cells (myeloblast or lymphoblast etc)
4. morphologic feature (auer rods, vacuoles , the size of the
nucleus etc)
13. 2-A bone marrow examination
• mostly has hypercellular B.M and few cases hypocellular
• 20% to 90% leukemic blasts at diagnosis or during relapse.
• The blast must present in the peripheral blood, unless the WBC count is markedly
decreased.
Acute leukemia
Bone Marrow Tryphine Biopsy
It is a histological test for bone marrow tissue to obtain the blood cells
Indication: If the peripheral blood indicate
1-hypocelluar
2-aplastic anemia
3-metastic cancer
Or the previous result indicate Dry tap bone marrow aspiration
14. 3-Flow cytometry or immunophenotypic studies
Monoclonal antibodies toward cell-type restricted antigens are used in this
highly specific method
CD markers Show for
1. blast cells
2. mature cells
and determine if it is
1. myeloid Cells types and count
2. lymphoid cells types and count
3. Normal or abnormal
15. 4- Chromosomal analysis
Chromosomal abnormalities studies is very important (diagnostic
and prognostic ) for
• AML
• ALL
critical in the diagnosis and treatment of AML.As in
ALL
Note
1-AML: Acute myeloblastic Leukemia
2-ALL: Acute Lymphoblastic Leukemia
16. 5-Cytochemical stains
Importance: very helpful in the diagnosis and classification of acute
leukemias
Specimens: bone marrow smears but may also be done on peripheral
smears
1. myeloperoxidase (MPO)
2. Sudan black B stain (SBB)
3. specific esterase stain (SE)
4. a non specific esterase stain (NSE)
5. Terminal deoxynucleotidyl transferase (TdT)
Types
20. Leukocyte Alkaline Phosphatase (LAP, Neutrophil Alkaline
Phosphatase, NAP)
Definition: The LAP score is a test done by performing a chemical reaction
on a blood smear
Evaluation:
1. The blood smear is viewed under a microscope, and the degree of granular staining
in mature neutrophils (bands and segs) is graded from 0 (no staining) to 4+ (dense
granular staining).
2. The LAP score is the sum of staining for 100 cells.
3. The normal range is 20 to 100.
Principle: The granular of bands and segs with the alkaline phosphatase
enzyme colored staining.
21. LAP Score
• Count 100 consecutive segs and
bands
• Score:
0 = no granules
1+ = occasional diffuse granules
2+ = moderate number of granules
3+ = many strongly positive granules
4+ = confluent strongly positive
granules
Example:
0 x 35 cells = 0
1+ x 30 cells = 30
2+ x 20 cells = 40
3+ x 10 cells = 30
4+ x 5 cells = 20
120
LAP Score
23. The two main conditions with
a low LAP score are
1. CML
2. paroxysmal nocturnal hemoglobinuria (PNH).
higher scores in
1. Polycythemia vera.
2. Myelofibrosis
3. Essential thrombocytopenia
4. leukemoid reactions
LAP score and related diseases
Precuations
1. Reject specimens collected in EDTA-anticoagulated (lavender-topped) tubes because EDTA inhibits the
activity of LAP
2. Results are invalid if the client is neutropenic (that is, <1000/mm3 neutrophils).
24. Instrumentation and leukemia
Platelets
The platelets count increased due to fragments of the
leukemic blasts, which are counted as platelets
To solve this problem
1. Platelets must be counted manually
2. Examination of a blood smear gives a more accurate
assessment of the platelet count in this circumstance.
25. Instrumentation and leukemia
WBC
Must check
1-The count on the blood smear
2-the DLC, if not agree count to 200 cells ,
report the average
Be carful for
1-the clot , old . Lipemic specimen, affects the results of CBC
2-the age of the patient (infant, child, adult) must be taken into account
3- newborns, toddlers, and young children, particular reference ranges must be taken
into account
4- a normal range is given, covering 95% of the values of healthy persons
5-The presence of abnormal cells needs clinical pathologist